August 30, 2010 (FinancialWire) (Go to http://www.financialwire.net/?s=ftrdnwswnd for all of today’s featured news.) — Endologix, Inc. (NASDAQ: ELGX), a developer of minimally invasive treatments for aortic disorders, said that it received CE Mark approval to market its expanded offering of Powerlink stent graft products and PowerFit Aortic Extensions in the European Union.

The company said it expects to launch the products in a limited market release in Europe during the fourth quarter of 2010, followed by a full product launch in 2011.

Endologix recently received U.S. Food and Drug Administration approval for these new products and they are currently in a limited market release in the U.S., with a full market release in the U.S. planned for the fourth quarter of 2010.

The CE Mark approval covers 31 new sizes of Powerlink main body bifurcated, proximal extension, and limb extension stent grafts. It also covers PowerFit Aortic Extensions, which are available in a range of sizes indicated to treat aortic necks ranging from 18 to 32 millimeters in diameter.

In addition, the PowerFit product line is available with longer stent lengths of up to 120 millimeters, to expand the treatment options.

The Powerlink System is California-based Endologix’s flagship product. It is an endovascular stent graft for the treatment of abdominal aortic aneurysms . AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement.

Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S.

Real-time, streaming research for companies and funds mentioned in FinancialWire(tm) news is available via the Investrend Research Syndicate (at http://investrend.stocksmart.com/ss/html/hpcompany.html). Current valuation analysis research for companies and funds mentioned in FinancialWire(tm) news is available via the Investrend Research Syndicate (at http://www.valuengine.com/rep/searchsrep?pid=42&srchfor=).

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public other companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (at http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation from subject entities, companies, equities, or representatives thereof, for its news, opinions or distributions. Further disclosure is posted at the FinancialWire(tm) website (at http://www.financialwire.net/disclosures.php and http://www.financialwire.net/2010/04/23/safe-harbor/). Additional resources for investors are also accessible via the FinancialWire(tm) website (at http://www.financialwire.net/2010/04/23/investor-resources/). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Copyright © MMX, FinancialWire(tm); All rights reserved.

[hlmsmlh] [rgltryrtl] [cmplncz] [gvrncnr] [hlthcrdp] [tchnlgy] [ntrntnlcmpnsbsnss] [erpnpre] [bsnnssb] [dvcmntnmc] [ftrdnwswnd] [gvrnmnt] [ntrctntcrt]